DayTwo, an Israeli company that analyzes gut microbiomes to assist with nutrition and glycemic control, has raised $31 million in Series B financing. Ofek Ventures and aMoon led the round, with additional support coming from prior backers Seventure Partners and Johnson & Johnson.
With this, the company brings its total backing to $48 million.
WHAT THEY DO
DayTwo’s platform asks patients to...
